uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced the granting of equity awards to 24 employees, totaling 40,000 restricted stock units (RSUs) and options for 26,000 ordinary shares on December 7, 2022. This follows additional grants made on October 31 and September 27, 2022. The options have exercise prices of $23.73, $18.62, and $18.04, respectively, based on closing prices on the grant dates. The options will vest over four years, while RSUs will vest over three years. These awards serve as inducements for new hires, emphasizing the company's growth strategy.

Positive

• Equity awards granted to 24 employees indicate a commitment to attracting talent.
• The options and RSUs align employee interests with company performance.

Negative

• None.

Argus Session date unavailable

+4.92% session move Open Argus

Details

News Market Reaction – QURE

The recorded move for QURE in the trading session of this news was +4.92%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their employment. The equity grants were approved by the Company’s board of directors on December 7, 2022, October 31, 2022, and September 27, 2022 (the “Grant Dates”) each in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate on December 7, 2022, 24 employees received 40,000 restricted stock units (“RSUs”) and options to purchase 26,000 ordinary shares of uniQure. Each option has an exercise price of $23.73 per share, the closing price per ordinary share as reported by Nasdaq on December 7, 2022. In the aggregate on October 31, 2022, 1 employee received 2,400 restricted stock units (“RSUs”) and options to purchase 1,500 ordinary shares of uniQure. Each option has an exercise price of $18.62 per share, the closing price per ordinary share as reported by Nasdaq on October 31, 2022. In the aggregate on September 27, 2022, 31 employees received 65,690 restricted stock units (“RSUs”) and options to purchase 55,970 ordinary shares of uniQure. Each option has an exercise price of $18.04 per share, the closing price per ordinary share as reported by Nasdaq on September 27, 2022.

Each option has a ten-year term and will vest over four years, with 25% of the original number of shares vesting on the first anniversary of the respective grant dates and an additional 6.25% of the shares vesting in approximately equal quarterly installments over the twelve successive quarters following the first anniversary. The RSUs will vest over three years, with one-third of the RSUs vesting annually on each successive anniversary of the Grant Date. The vesting of each grant of options and RSUs is subject to the employee’s continued service with the Company through the applicable vesting dates.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com

uniQure Contacts: FOR INVESTORS: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 m.cantor@uniQure.com

Chiara Russo Direct: 617-306-9137 Mobile: 617-306-9137 c.russo@uniQure.com

FOR MEDIA: Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 t.malone@uniQure.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards were granted by uniQure on December 7, 2022?

On December 7, 2022, uniQure granted 40,000 RSUs and options for 26,000 shares at an exercise price of $23.73.

How many employees received equity awards from uniQure?

A total of 24 employees received equity awards on December 7, 2022.

What is the significance of the equity awards by uniQure?

The equity awards serve as an inducement to attract new employees and align their interests with the company's success.

What are the vesting terms for the equity awards granted by uniQure?

The options vest over four years, while RSUs vest over three years, with specific annual and quarterly vesting schedules.

What was the exercise price for the options granted by uniQure?

The exercise prices for the options granted were $23.73, $18.62, and $18.04, based on the respective grant dates.